Regeneron beats fourth-quarter revenue estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron (REGN) jumps on robust Q4 earnings
February 2, 2024 7:32 AM ESTShares of Regeneron Pharmaceuticals (NASDAQ: REGN) jumped more than 5% in pre-market trading Friday after the pharma company posted better-than-anticipated Q4 earnings.
Regeneron reported adjusted earnings per share (EPS) of $11.86 for the fourth quarter, beating the consensus projection of $10.62. Revenue came in at $3.43 billion,... More
